Point-of-care CAR T manufacturing solutions: can 1 model fit all?
作者信息
Urbano-Ispizua Álvaro, Shah Nirav N, Kekre Natasha
机构信息
Department of Medicine, Institute of Cancer and Blood Diseases, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.
Division of Hematology and Oncology, Bone Marrow Transplant and Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI.
出版信息
Blood Adv. 2024 Dec 10;8(23):6133-6136. doi: 10.1182/bloodadvances.2024012982.
Abstract
摘要
相似文献
1
Point-of-care CAR T manufacturing solutions: can 1 model fit all?床旁CAR-T细胞制造解决方案：一种模式能适用于所有情况吗？
Blood Adv. 2024 Dec 10;8(23):6133-6136. doi: 10.1182/bloodadvances.2024012982.
2
Point-of-care manufacturing of anti-CD19 CAR-T cells using a closed production platform: Experiences of an academic in Thailand.使用封闭生产平台进行抗CD19嵌合抗原受体T细胞的床旁制造：一位泰国学者的经验
Mol Ther Oncol. 2024 Oct 5;32(4):200889. doi: 10.1016/j.omton.2024.200889. eCollection 2024 Dec 19.
3
Revolutionizing CAR T-Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility.颠覆 CAR T 细胞疗法：基因工程和制造创新，提高疗效和可及性。
Int J Mol Sci. 2024 Sep 26;25(19):10365. doi: 10.3390/ijms251910365.
4
Surveying local CAR T-cell manufacturing processes to facilitate standardization and expand accessibility.调研当地嵌合抗原受体T细胞制造流程，以促进标准化并扩大可及性。
J Transl Med. 2025 May 6;23(1):507. doi: 10.1186/s12967-025-06400-x.
5
Decentralized Point-of-Care Manufacturing of CD19 Chimeric Antigen Receptor T Cells in Mexico.墨西哥CD19嵌合抗原受体T细胞的分散式即时制造
JCO Glob Oncol. 2025 Apr;11:e2400581. doi: 10.1200/GO-24-00581. Epub 2025 Apr 18.
6
Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas.用于 B 细胞淋巴瘤的嵌合抗原受体-T 设计和应用的挑战和解决方案。
Br J Haematol. 2023 Oct;203(2):161-168. doi: 10.1111/bjh.19001. Epub 2023 Jul 24.
7
Promises and challenges of a decentralized CAR T-cell manufacturing model.分散式嵌合抗原受体T细胞制造模式的前景与挑战
Front Transplant. 2023 Sep 5;2:1238535. doi: 10.3389/frtra.2023.1238535. eCollection 2023.
8
CAR assembly line: Taking CAR T-cell manufacturing to the next level.嵌合抗原受体（CAR）装配线：将CAR-T细胞制造提升到新高度。
Best Pract Res Clin Haematol. 2024 Dec;37(4):101595. doi: 10.1016/j.beha.2024.101595. Epub 2024 Dec 6.
9
Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanoma.临床级自体 CD20 CAR T 细胞的自动化制造和鉴定用于治疗 III/IV 期黑色素瘤患者。
Front Immunol. 2024 Sep 25;15:1328368. doi: 10.3389/fimmu.2024.1328368. eCollection 2024.
10
Cost-effective strategies for CAR-T cell therapy manufacturing.嵌合抗原受体T细胞（CAR-T）疗法生产的经济高效策略。
Mol Ther Oncol. 2025 Apr 3;33(2):200980. doi: 10.1016/j.omton.2025.200980. eCollection 2025 Jun 18.
引用本文的文献
1
Implementation of a quality management system for decentralized manufacturing of cell and gene therapy products - technical and regulatory considerations.细胞和基因治疗产品分散式生产质量管理体系的实施——技术与法规考量
Front Med (Lausanne). 2025 Aug 5;12:1591751. doi: 10.3389/fmed.2025.1591751. eCollection 2025.
2
Harnessing the promises of cell therapy, gene therapy, and regenerative medicine in Québec, Canada.在加拿大魁北克利用细胞疗法、基因疗法和再生医学的前景。
Front Med (Lausanne). 2025 Jun 3;12:1581058. doi: 10.3389/fmed.2025.1581058. eCollection 2025.
3
From myth to bedside: a scoping review of the applications of the chimeric antigen receptor in rheumatology.从神话到临床：嵌合抗原受体在风湿病学应用的范围综述
Clin Exp Med. 2025 Jun 6;25(1):189. doi: 10.1007/s10238-025-01717-9.
4
How to democratize cell and gene therapy: A global approach.如何使细胞和基因疗法民主化：一种全球方法。
Mol Ther. 2025 May 7;33(5):2082-2090. doi: 10.1016/j.ymthe.2025.03.061. Epub 2025 Apr 2.
5
Charting the course for CAR T-cell manufacturing.绘制嵌合抗原受体（CAR）T细胞制造的路线图。
Blood Adv. 2024 Dec 10;8(23):6131-6132. doi: 10.1182/bloodadvances.2024014653.
本文引用的文献
1
Enhancing pediatric access to cell and gene therapies.提高儿科细胞和基因治疗的可及性。
Nat Med. 2024 Jul;30(7):1836-1846. doi: 10.1038/s41591-024-03035-1. Epub 2024 Jun 17.
2
Chimeric Antigen Receptor T-Cell Access in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Association of Access with Social Determinants of Health and Travel Time to Treatment Centers.嵌合抗原受体 T 细胞输注治疗复发/难治性大 B 细胞淋巴瘤患者：输注机会与健康的社会决定因素和前往治疗中心的交通时间的关联。
Transplant Cell Ther. 2024 Jul;30(7):714-725. doi: 10.1016/j.jtct.2024.04.017. Epub 2024 Apr 30.
3
Cutting-edge CAR-T cancer therapy is now made in India - at one-tenth the cost.前沿的嵌合抗原受体T细胞（CAR-T）癌症疗法如今在印度生产，成本仅为原来的十分之一。
Nature. 2024 Mar;627(8005):709-710. doi: 10.1038/d41586-024-00809-y.
4
Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed.用于儿童癌症的嵌合抗原受体（CAR）T细胞产品：为何需要替代开发路径。
J Clin Oncol. 2024 Jan 20;42(3):253-257. doi: 10.1200/JCO.23.01314. Epub 2023 Nov 27.
5
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study.ARI0002h 是一种人源化、BCMA 导向的 CAR T 细胞疗法，采用分次初始输注和加强剂量，用于治疗复发或难治性多发性骨髓瘤患者（CARTBCMA-HCB-01）：一项单臂、多中心、学术性的初步研究。
Lancet Oncol. 2023 Aug;24(8):913-924. doi: 10.1016/S1470-2045(23)00222-X. Epub 2023 Jul 3.
6
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.移植后环磷酰胺为基础的移植物抗宿主病预防。
N Engl J Med. 2023 Jun 22;388(25):2338-2348. doi: 10.1056/NEJMoa2215943.
7
Place of care manufacturing of chimeric antigen receptor cells: Opportunities and challenges.嵌合抗原受体细胞的产地制造：机遇与挑战。
Semin Hematol. 2023 Jan;60(1):20-24. doi: 10.1053/j.seminhematol.2023.01.001. Epub 2023 Jan 24.
8
CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies.CLIC-01：非冷冻保存嵌合抗原受体 T 细胞的生产和分发，用于治疗 CD19 阳性血液系统恶性肿瘤患者。
Front Immunol. 2022 Dec 19;13:1074740. doi: 10.3389/fimmu.2022.1074740. eCollection 2022.
9
Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.托珠单抗预防非霍奇金淋巴瘤患者抗 CD19 CAR-T 细胞治疗后免疫效应细胞相关神经毒性综合征。
Front Immunol. 2021 Oct 12;12:745320. doi: 10.3389/fimmu.2021.745320. eCollection 2021.
10
Is Hospital Exemption an Alternative or a Bridge to European Medicines Agency for Developing Academic Chimeric Antigen Receptor T-Cell in Europe? Our Experience with ARI-0001.医院豁免是在欧洲开发学术嵌合抗原受体 T 细胞的欧洲药品管理局的替代方案或桥梁吗？我们在 ARI-0001 方面的经验。
Hum Gene Ther. 2021 Oct;32(19-20):1004-1007. doi: 10.1089/hum.2021.168.
Zotero 插件